Retinopathy of Prematurity Follow-up
- Author: Mounir Bashour, MD, CM, FRCS(C), PhD, FACS; Chief Editor: Hampton Roy Sr, MD more...
Further Outpatient Care
- Any premature infant should continue to be monitored until active disease has subsided.
- Since 20% of premature babies develop strabismus and refractive errors, a pediatric ophthalmologist should screen them every 6 months, until age 3 years.
- Up to 10% of premature babies may develop glaucoma in later years. Eye examinations should be a part of their annual examinations.
Transfer
- Transfer the infant to a NICU that can handle the disease and the required surgical intervention if necessary.
Deterrence/Prevention
- The Light-ROP study evaluated the role of light in stimulating the development of ROP. Patients were either exposed to normal light conditions in the nursery or shielded from ambient light conditions. There was no difference in the number of patients developing ROP in either group.
Complications
- Loss of vision even with aggressive surgical treatment
- Amblyopia due to high refractive errors
- Strabismus
- Glaucoma
- Retinal detachment
Prognosis
- The prognosis is guarded until zone 3 is reached.
Patient Education
- Awareness of the risk of potential visual loss from amblyopia, strabismus, retinal detachment, or glaucoma
- Possible need for repeated surgical procedures
- Possible patching for amblyopia, thick glasses for myopia, or possible strabismus surgery
Terry TL. Extreme prematurity and fibroplastic overgrowth of persistent vascular sheath behind each crystalline lens I. Preliminary report. Am J Ophthalmol. 1942;25:203-4.
Campbell K. Intensive oxygen therapy as a possible cause for retrolental fibroplasia. A clinical approach. Med J Austr. 1951;2:48-50.
Kretzer FL, Hittner HM. Retinopathy of prematurity: clinical implications of retinal development. Arch Dis Child. Oct 1988;63(10 Spec No):1151-67. [Medline].
Ashton N. Oxygen and the retinal blood vessels. Trans Ophthalmol Soc U K. Sep 1980;100(3):359-62. [Medline].
Csak K, Szabo V, Szabo A, et al. Pathogenesis and genetic basis for retinopathy of prematurity. Front Biosci. Jan 1 2006;11:908-20. [Medline].
Fielder AR, Shaw DE, Robinson J, et al. Natural history of retinopathy of prematurity: a prospective study. Eye. 1992;6 (Pt 3):233-42. [Medline].
Varughese S, Gilbert C, Pieper C, et al. Retinopathy of prematurity in South Africa: an assessment of needs, resources and requirements for screening programmes. Br J Ophthalmol. Jul 2008;92(7):879-82. [Medline].
Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. Nov 1991;98(11):1628-40. [Medline].
Wallace DK, Freedman SF, Hartnett ME, Quinn GE. Predictive Value of Pre-plus Disease in Retinopathy of Prematurity. Arch Ophthalmol. May 2011;129(5):591-6. [Medline].
Tolsma KW, Allred EN, Chen ML, et al. Neonatal bacteremia and retinopathy of prematurity: the ELGAN study. Arch Ophthalmol. Dec 2011;129(12):1555-63. [Medline].
Lajoie A, Koreen S, Wang L, et al. Retinopathy of prematurity management using single-image vs multiple-image telemedicine examinations. Am J Ophthalmol. Aug 2008;146(2):298-309. [Medline].
Dempsey E, McCreery K. Local anaesthetic eye drops for prevention of pain in preterm infants undergoing screening for retinopathy of prematurity. Cochrane Database Syst Rev. Sep 7 2011;9:CD007645. [Medline].
Repka MX, Hardy RJ, Phelps DL, et al. Surfactant prophylaxis and retinopathy of prematurity. Arch Ophthalmol. May 1993;111(5):618-20. [Medline].
Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Ophthalmology. Jan 2011;118(1):176-83. [Medline].
Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. Feb 17 2011;364(7):603-15. [Medline].
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome--structure and function. Arch Ophthalmol. Oct 1990;108(10):1408-16. [Medline].
Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. Dec 2003;121(12):1684-94. [Medline].
Laser ROP Study Group. Laser therapy for retinopathy of prematurity. Arch Ophthalmol. Feb 1994;112(2):154-6. [Medline].
Phelps DL. Retinopathy of prematurity: an estimate of vision loss in the United States--1979. Pediatrics. Jun 1981;67(6):924-5. [Medline].
Repka MX, Tung B, Good WV, et al. Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP). Arch Ophthalmol. Jan 2006;124(1):24-30. [Medline].
Reynolds JD, Hardy RJ, Kennedy KA, et al. Lack of efficacy of light reduction in preventing retinopathy of prematurity. Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group. N Engl J Med. May 28 1998;338(22):1572-6. [Medline].
Schaffer DB, Palmer EA, Plotsky DF, et al. Prognostic factors in the natural course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. Feb 1993;100(2):230-7. [Medline].
Section on Ophthalmology American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. Feb 2006;117(2):572-6. [Medline].
Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. Feb 2000;105(2):295-310. [Medline].
The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol. Aug 1984;102(8):1130-4. [Medline].

